

Mesoblast – QuickView

22 March 2013

Investment summary: Little margin for risk

Mesoblast's current valuation assumes a high probability of success for its stem cell technology, but it does hold the leadership position in this field. A proposed large Phase III study of Revascor in congestive heart failure (CHF), which is to be fully funded by co-development partner Teva, holds promise of both validating the company's mesenchymal precursor cell (MPC) platform and moving stem cell therapeutics closer to commercial reality in the US. However, an EV of A\$1.59bn, when compared to peers, belies the risk of any clinical trial setbacks and potential competition from rival approaches to indications being targeted.

Revascor to enter Phase III in congestive heart failure

A planned Phase III trial of lead product Revascor in 1,700 patients with CHF should start in 2013, with co-development partner Teva bearing all costs. Early data is positive but limited. A 60-patient Phase II trial examining the safety and efficacy of three doses of Revascor showed patients treated with a single intra-cardiac injection of the highest dose had no hospitalisation events for decompensated heart failure or cardiac-related deaths, over a mean follow-up period approaching three years.

Stem cell therapy - promising but risky

Despite the potential of engineered stem cell therapies to address major unmet needs, the technology is unproven and there remains considerable clinical and regulatory risk. The FDA is yet to approve such a treatment.

Multiple clinical programmes - single technology platform

The recent A\$170m capital raising extends the cash runway for funding of multiple clinical programmes (six Phase II, five preclinical) through to 2016, based on its current US\$65m pa burn rate, during which time clinical data should be reported. In addition to cardiovascular indications, clinical trials are also targeting degenerative disc disease, type-2 diabetes and wet age-related macular degeneration (AMD). Although this portfolio approach provides multiple shots at goal, clinical risk inherent in each trial is compounded overall by the use of a single technology platform.

Valuation: Assumes high probability of clinical success

An EV of A\$1.59bn, based on net cash of A\$332m (March 2013, including A\$170m raising), assumes a high probability of success across a development pipeline built on a single technology platform with limited clinical efficacy data to date. By comparison, Osiris, which has the, albeit niche, allogenic stem cell therapy Prochymal (remestemcel-L) approved in Canada in 2012, has an EV of US\$338m.

Consensus estimates

Year End	Revenue (A\$m)	PBT (A\$m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/11	14.6	92.2	41.8	0.0	N/A	N/A
12/12	27.7	(48.7)	(25.2)	0.0	N/A	N/A
12/13e	17.0	(62.4)	(22.1)	0.0	N/A	N/A
12/14e	16.6	(75.1)	(27.6)	0.0	N/A	N/A

Source: Bloomberg

Price A\$6.2
Market cap A\$1,951m

Share price graph



Share details

Code MSB
Listing ASX
Sector Pharma & biotech
Shares in issue 314.8m

Business

Mesoblast is an ASX-listed biotechnology company with a large R&D pipeline built on a proprietary stem cell technology. Mesoblast is developing allogenic cell therapies based on mesenchymal precursor cells in the areas of cardiovascular disease, diabetes, oncology, eye disease and orthopaedic diseases.

Bull

- Strong financial position.
- Intellectual property/patent position.
- Teva co-development of Revascor.

Bear

- Single platform technology.
- Clinical development/regulatory risk.
- Competitive landscape.

Analysts

Chris Kallos +61 (0)2 9258 1160
Robin Davison +44 (0)20 3077 5737
healthcare@edisoninvestmentresearch.co.uk

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

EDISON INVESTMENT RESEARCH LIMITED

Edison Investment Research Limited (Edison) is a leading international investment research company. Edison and its subsidiaries (Edison Group) have won industry recognition, with awards both in Europe and internationally. The team of 110 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison's research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York, Sydney and Wellington. Edison is authorised and regulated by the United Kingdom's Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only.

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c)(1)(a), (b) and (c) of the FAA). It is not intended for retail clients. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct an investment business and, accordingly, does not hold any positions in the securities mentioned in this report. However, their respective directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

Registered in England, number 4794244, Edison Investment Research Limited is authorised and regulated by the United Kingdom Financial Services Authority. www.edisoninvestmentresearch.co.uk. Registered on the New Zealand Financial Service Providers Register, number 247505, Edison Investment Research (NZ) Limited is registered to provide wholesale and/or generic financial adviser services and is regulated by the New Zealand Financial Markets Authority.

London +44 (0)20 3077 5700
Lincoln House, 296-302 High Holborn
London, WC1V 7JH, UK

New York +1 646 653 7026
245 Park Avenue, 39th Floor
New York, NY 10167, USA

Wellington + 64 4894 8555
Level 15, 171 Featherston St
Wellington 6011, NZ

Sydney +61 (0)2 9258 1162
Level 33, Australia Square, 264 George St,
Sydney, NSW 2000, Australia